Brian Earp on Using Drugs to Fall In or Out of Love

Answer in brief Brian D. Earp argued on Modern Wisdom that drugs could potentially help people either renew a relationship or loosen an attachment, but not by precisely switching love on or off. He described love as simultaneously biological, psychological, and social; medication acts most directly on biology, while its relational meaning depends on therapy, personal interpretation, and what partners do afterward. He saw supervised MDMA or psychedelic-assisted therapy as possible ways to interrupt fear and entrenched interaction patterns, allowing couples to reassess shared values or recover inaccessible feelings. Conversely, existing drugs such as SSRIs may unintentionally weaken libido, emotion, and attachment. His position was cautiously permissive rather than promotional: current interventions are blunt, outcomes are uncertain, and ethical acceptability depends heavily on consent, context, social pressure, and the seriousness of the suffering involved. 0:00, 7:00, 10:30, 18:05, 23:55, 1:05:20

How drugs might help people fall back in love Earp rejected a simple chemical model in which love is merely a brain state that can be turned up pharmacologically. His framework treated romantic love as a product of interacting biological, psychological, and social processes. A drug can alter neurobiology, but it cannot by itself supply a couple with compatible values, repair their history, or determine how they should interpret what happens. This is why his examples generally involved medication as part of a wider relational process rather than as a standalone love potion. 7:00, 12:15

His most developed positive case concerned psychedelic-assisted couples work. Long-term partners can become trapped in repetitive interpretations and defensive routines, making it difficult to encounter one another outside the accumulated script of the relationship. Earp proposed that an altered state might temporarily disrupt those patterns, creating room to revisit shared commitments, investigate neglected feelings, or recover a sense of connection that ordinary conversation no longer reaches. The relevant promise is therefore greater flexibility, not the guaranteed production of affection. 0:00, 1:07:40, 1:08:50

He gave MDMA a related but somewhat more specific therapeutic role. In a safe setting with professional supervision, dampening an immediate fear response might let partners discuss betrayal, trauma, resentment, or vulnerability without instantly returning to defensive conflict. That could make a painful conversation more constructive, but the drug would still be an enabling condition rather than the healing act itself. Earp located much of the possible benefit in the meaning people make from vulnerability and in whether they can translate insights from the altered state into everyday conduct. 10:30, 12:15

Psilocybin supplied a possible mechanism for this loosening. Earp described it as acting through serotonin receptors and reducing brain activity associated with the persistent experience of a bounded self. A weaker felt division between self and other could make a partner appear differently or soften rigid self-protective narratives. Yet the acute state ends. The couple must then decide whether the new perspective was illuminating, misleading, transient, or worthy of incorporation into the relationship. 59:30, 1:02:25

Falling out of love and suppressing harmful attachment Earp also treated medication as something that may weaken love unintentionally. He noted reports from people taking SSRIs who experienced reduced sexual desire and emotional blunting, sometimes alongside a perceived loss of love for a long-term partner. He used such accounts to argue that drug research should examine interpersonal outcomes, not merely whether symptoms improve for the medicated individual. A treatment can benefit one person clinically while also changing intimacy, attachment, or the future of a partnership. The supplied evidence characterizes these relationship effects as anecdotal or of unspecified evidential status, not as an established frequency or predictable SSRI outcome. 19:15, 23:55

The more deliberate anti-love case concerned attachments that keep someone in danger. Earp could see a possible role for medication in helping a person loosen an attachment to an abusive partner, particularly if persistent bonding makes leaving psychologically difficult. But he strongly resisted treating pharmacology as the primary answer. Protection, policing, social support, and accountability for the abuser remain central; placing responsibility on the victim to medicate away attachment would misidentify who must change and risk becoming another form of victim-blaming. 15:10

He also considered voluntary suppression of dangerous sexual desire in adults who are exclusively attracted to children, do not want to offend, and may experience profound distress or suicidal thinking. In that case, an imperfect anti-desire intervention might be ethically defensible when requested by the person and when the likely reduction in suffering and risk outweighs side effects. His argument was a harm-reduction proposal for a severe situation, not a claim that present medication can selectively remove one target of attraction without affecting the rest of a person’s emotional or sexual life. 16:55, 18:05, 33:15

Consent, coercion, and unequal social pressure Consent was necessary in Earp’s account but not sufficient to settle every case. A technology that gives adults voluntary influence over their attractions might appear to expand liberty and self-creation. In an ideal society, that could support a broad freedom to shape one’s emotional life. In an unequal society, however, formally voluntary choices can be distorted by family rejection, stigma, religious pressure, or discrimination. Earp therefore suggested that the asymmetric pressure placed on sexual minorities may be a reason not to develop or introduce attraction-altering technologies yet, even if some hypothetical uses could be autonomous. 30:20

His clearest boundary concerned children. Minors should not have drugs imposed on them to suppress or redirect sexuality. This prohibition follows from both their vulnerability to adult authority and the history of attempts to normalize sexual minorities through coercive treatment. The broader implication is that technical capacity does not create moral permission: who chooses, under what pressures, and for whose benefit matter as much as the intended biological effect. 27:25, 30:20

Earp’s position also acknowledged that existing tools are poorly targeted. A medication intended to reduce attachment to one person may alter libido, mood, motivation, or relationships more generally. Nevertheless, he did not treat imprecision as an automatic veto. Where suffering is severe, a consenting adult might reasonably accept diffuse or uncertain effects if the expected overall benefit is large enough. That is a familiar risk-benefit argument, but it demands greater caution when social coercion is present or the proposed recipient cannot provide meaningful consent. 18:05, 33:15

Authenticity and whether a medicated feeling is real Earp challenged the assumption that chemically influenced love must be false. A drug might cover over an unwanted feeling, but it could also remove fear, inhibition, or a rigid psychological barrier that prevents someone from accessing feelings they recognize as their own. The same substance might help one person evade an honest confrontation while enabling another to disclose something previously inaccessible. Authenticity therefore cannot be inferred simply from the presence or absence of pharmacological influence; it depends on the person’s purpose, context, and relationship to the resulting emotion. 47:50, 49:35

One account he discussed links authenticity to reflective endorsement. On this view, an altered emotion or behavior can belong to the person if, after reflection, they accept it as expressing who they want to be. That does not eliminate hard cases: endorsement itself may change, and a partner may reasonably wonder whether the post-drug identity is continuous with the person they committed to. Earp’s response was not that medication leaves identity untouched, but that drug-induced transformation is not categorically unique. Meditation, religious conversion, parenthood, and other ordinary experiences can also reorganize values and destabilize relationships. 43:10, 52:30

Because prediction remains imperfect, the effect on a couple cannot be read directly from the pharmacology. A new perspective may become part of a shared life if both partners can interpret and integrate it, or it may expose a divergence they cannot reconcile. The drug’s temporary action does not decide which interpretation is correct. Agency returns in the aftermath, when those involved determine whether to cultivate the altered insight, reject it, or reconsider the relationship itself. 44:55, 1:02:25

Earp’s overall stance Earp described moving away from a previously anti-drug outlook after encountering many reports of deeply beneficial experiences. That personal change did not lead him to endorse enhancement indiscriminately. His position remained cautious: pharmacological interventions can sometimes create access to valuable experiences, but their consequences depend on therapeutic structure, social conditions, individual aims, and later integration. His central practical proposal was to treat drugs as possible tools for interrupting entrenched habits, after which people still have to construct healthier patterns deliberately. 1:05:20, 1:08:50

This produces an asymmetrical but coherent view of falling in and out of love. Facilitating connection may be defensible when consenting partners use a temporary altered state to communicate more openly. Weakening attachment may be defensible when it relieves grave suffering or reduces a serious risk, but it becomes ethically suspect when imposed, used as a substitute for protecting victims, or introduced into a society where minorities face unequal pressure to change. Across both directions, Earp emphasized neither chemical destiny nor total personal control, but a combination of biological influence and subsequent human interpretation. 10:30, 15:10, 16:55, 27:25, 30:20, 44:55

What this does not establish The episode does not establish that any available drug can reliably make a particular person love or stop loving another person. The serotonin-transporter findings Earp cited came from observational studies of people in obsessive early-stage romantic love; the reported normalization after that phase is an association, not proof that manipulating serotonin will predictably create or extinguish love. He presented pharmacological manipulation as a possibility rather than a demonstrated treatment. 8:45

Nor do the mechanistic descriptions of psilocybin establish a clinical relationship benefit. Activity at serotonin receptors and a weakened sense of self may help explain features of an altered state, but a plausible mechanism is not controlled evidence that couples become happier, safer, or more stable. Earp’s proposals about rekindling connection and disrupting relational habits remain expert interpretations about potential applications. 0:00, 59:30, 1:07:40, 1:08:50

The episode included controlled human research on intranasal oxytocin, but Earp himself judged its results insufficiently robust, durable, or consistently replicable. That caution cuts against treating oxytocin as a validated bonding intervention. Likewise, reports of SSRIs changing feelings toward partners highlight a research question but do not reveal prevalence, causality, dose-response relationships, or which patients are at risk. Controlled findings, observational associations, proposed mechanisms, expert ethical analysis, and patient anecdotes carry different evidential weight and cannot be combined into a single claim of effectiveness. 9:55, 19:15, 23:55

Finally, agreement within a podcast conversation would not constitute scientific or ethical consensus. The evidence supplied does not cover clinical protocols, comparative trials, long-term relationship outcomes, adverse-event rates, or validated methods for targeting one attachment without wider emotional effects. Earp’s argument is best understood as a framework for investigating interpersonal drug effects and judging hypothetical uses, with explicit recognition that current interventions are messy and their consequences uncertain. 18:05, 19:15, 44:55

Sources

• Modern Wisdom: The Ethics Of Using Drugs To Fall In & Out Of Love - Brian D. Earp - #268